Intestinal CYP3A and P-glycoprotein (P-gp) decrease the intestinal absorption of substrate drugs. Since substrate specificity of CYP3A often overlaps that of P-gp, and estimation of their saturability in the intestine is difficult, dose-dependent F a F g (fraction of the administered drugs that reach the portal blood) of substrate drugs and the relative importance of CYP3A and P-gp have not been clarified in many cases. Thus, we tried to establish the universal methodology for predicting the in vivo absorption of several CYP3A and/or P-gp substrates from in vitro assays. One of the key points is to set up the scaling factor (SF), correcting the difference between the observed in vivo clearance and the predicted clearance from in vitro data. The SFs of V max for CYP3A (SF CYP3A ) and P-gp (SF P-gp ) were simultaneously optimized to explain the F a F g of CYP3A and/or P-gp substrate drugs. The best predictability of F a F g was achieved when considering both SF CYP3A and SF P-gp . The simulation also clarified the relative importance of CYP3A and P-gp in determining F a F g . In particular, the nonlinear intestinal absorption of verapamil was caused by the saturation of intestinal CYP3A, whereas that of quinidine was governed by the saturation of both CYP3A and P-gp. In addition, the dose-dependent F a F g of selective and dual CYP3A and/or P-gp substrates was well predicted. We therefore propose a methodology for predicting the F a F g of drugs using a mathematical model with optimized SF CYP3A and SF P-gp . Our methodology is applicable to in vitro-in vivo extrapolation of intestinal absorption, even if absolute in vivo functions of enzymes/transporters are unclear.
Introduction
It is well known that CYP3A and P-glycoprotein (P-gp) in the enterocytes contribute to the suppression of intestinal absorption of substrate drugs. CYP3A involves the decrease in the fraction of absorbed drugs that reach the portal vein. Whereas CYP3A4 is the dominant CYP3A isoform in the liver and small intestine, CYP3A5 is also found in these tissues, and its expression is polymorphic (Wrighton et al., 1990; Guengerich, 1995; Paine et al., 1997) . In addition, P-gp plays a role in the drug efflux from enterocytes to the intestinal lumen (Thiebaut et al., 1987; Saitoh and Aungst, 1995; Wacher et al., 1998) . Thus, the saturation of CYP3A-mediated metabolism and/or P-gp-mediated efflux may lead to the increase in the intestinal absorption as the dose increases. Indeed, it has been reported that felodipine, midazolam, and sildenafil (substrates of CYP3A); celiprolol and talinolol (substrates of P-gp); and indinavir and 3-ethyl-5-{5-[(4-ethylpiperazin-1-yl)sulfonyl]-2-propoxyphenyl}-2-(pyridin-2-ylmethyl)-2,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one (UK-393,664) (substrates of both CYP3A and P-gp) show nonlinear pharmacokinetics at therapeutically relevant doses, possibly caused by the saturation of intestinal CYP3A and/or P-gp (Bornemann et al., 1985; Nakashima et al., 1988 Nakashima et al., , 1992 Wetterich et al., 1996; Yeh et al., 1998; Nichols et al., 2002; Abuasal et al., 2012) .
Microdose (MD) studies are useful to obtain information on human clinical pharmacokinetics of new drug candidates in the early stage of drug development. Some researchers are concerned with whether the dosenormalized drug concentration at therapeutic dose (ThD) is identical to that at MD . In theory, if all of the molecules involved in metabolism and transport are not saturated at ThD, drug concentration normalized by dose should be equal, regardless of the dose. We and other groups have already demonstrated the linear pharmacokinetics of drugs at MD and ThD for several MD studies (Lappin et al., 2006 (Lappin et al., , 2011 Yamane et al., 2007) . However, it has been pointed out that the nonlinearity between MD and ThD renders it difficult to predict the pharmacokinetics. Based on the pharmacokinetic theory, although low bioavailability of drugs is confirmed in an MD study, it is still possible that drugs show high bioavailability in the clinical situation if the saturation of CYP3A-mediated metabolism and/or P-gp-mediated efflux occurs at a high dose, but not at MD. This may lead to the incorrect conclusion of poor bioavailability, which is not appropriate for a new chemical entity during exploratory research. Thus, it is important to quantitatively clarify the role of the saturation of intestinal CYP3A and P-gp in predicting the pharmacokinetics at ThD from the results of MD study.
Yu and Amidon (1999) proposed a compartmental absorption and transit model to simulate the rate and extent of drug absorption. The compartmental absorption and transit model was subsequently enhanced by Simulations Plus, Inc. (Lancaster, CA) to reflect more physiologic gastrointestinal characteristics along with an enterocyte compartment to account for gut metabolism, and was called the advanced compartmental absorption and transit (ACAT) model. The ACAT model was proposed to mechanistically predict drug dissolution and intestinal absorption including gut metabolism and active transport processes after oral administration (Agoram and et al., 2001) . Bolger et al. (2009) demonstrated the ability of the ACAT model to simulate the nonlinear pharmacokinetics for substrates of influx and efflux transporters in the intestine. Theoretically, in vivo functions of enzymes/transporters should be predicted from in vitro metabolic/transport activities simply by scaling up in vitro parameters by using the ratio of expression level of molecules in whole tissue to that in the expression systems. However, in the actual situations, various reports indicated that some empirical scaling factors (SFs) further improved the predictability of cytochrome P450 (P450)-mediated metabolism and transporter-mediated membrane permeation (e.g., Hirota et al., 2001; Naritomi et al., 2001; Galetin et al., 2004; Emoto and Iwasaki, 2007) . Differences in activity per unit enzyme amount between cDNA-expressed P450s and liver microsomes are sometimes caused by the levels of accessory proteins and cofactors and buffer composition (Venkatakrishnan et al., 2000; Taguchi et al., 2001; Kudo et al., 2016) . Materials, experimental conditions, and analytical methods also affect interlaboratory differences in in vitro parameters. Moreover, information on an absolute expression level of P-gp in each region of human intestine is still lacking. Thus, the prediction of intestinal absorption of drugs by "pure bottom-up approach" is not always successful for various reasons. Therefore, we tried to establish an appropriate method for the quantitative prediction of the dose-dependent intestinal availability (F a F g ) of drugs based on the in vitro saturation kinetics and relative importance of CYP3A and P-gp in their nonlinear pharmacokinetics by the ACAT model. In addition, we aimed to discriminate whether or not pharmacokinetics of CYP3A/P-gp substrates maintain linearity even at the therapeutic dose.
Materials and Methods
Materials. Felodipine, midazolam, triazolam, and verapamil hydrochloride were purchased from Wako Pure Chemicals (Kyoto, Japan). Digoxin and quinidine sulfate dehydrate salt were purchased from Sigma Chemical Co., Ltd. (St. Louis, MO). Sildenafil citrate, talinolol, and fexofenadine hydrochloride were purchased from Toronto Research Chemicals Inc. (North York, Canada). Celiprolol hydrochloride was purchased from AvaChem Scientific (San Antonio, TX). Indinavir and saquinavir mesylate were purchased from the U.S. Pharmacopeial Convention (Rockville, MD). Recombinant human CYP3A4 and CYP3A5 supersomes were purchased from BD Gentest Co. (Woburn, MA). Human intestine homogenate was purchased from Biopredic International (Rennes, France). Dulbecco's modified Eagle's medium with 4500 mg/l glucose, nonessential amino acids, and penicillin-streptomycin solution were purchased from Gibco BRL (Gaithersburg, MD). All other reagents used were of analytical grade.
In Vitro Assay for CYP3A4-Mediated Metabolism. Kinetic parameters for CYP3A4-mediated metabolism were estimated using a substrate depletion assay (Obach and Reed-Hagen, 2002) . Recombinant human CYP3A4 microsomes (10 pmol of P450/ml) and different concentrations of felodipine (0.03-10 mM), midazolam (0.05-5 mM), sildenafil (0.03-30 mM), triazolam (0.5-100 mM), indinavir (0.03-10 mM), quinidine (2-100 mM), saquinavir (0.03-10 mM), or verapamil (0.5-50 mM) were incubated in 100 mM KH 2 PO 4 (pH 7.4) containing 3.3 mM MgCl 2 for 5 minutes at 37°C. The reaction was initiated by the addition of 1.3 mM NADPH in a total volume of 500 ml. Reaction mixture (0.05 ml) was removed at 0, 0.5, 1, 2, 5, 10, and 20 minutes. The reaction was stopped by the addition of 50 ml of acetonitrile containing an internal standard, triazolam (for felodipine and midazolam), diazepam (for sildenafil), saquinavir (for indinavir), dextromethorphan (for verapamil and quinidine), and indinavir (for saquinavir) on ice. The mixture was centrifuged for 5 minutes at 20,400 Â g at 4°C, and the supernatants were collected. Terminated reaction mixtures were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition, nonspecific binding to microsomes was estimated by ultracentrifugation. All substrates were incubated with recombinant human CYP3A4 microsomes in 100 mM KH 2 PO 4 (pH 7.4) containing 3.3 mM MgCl 2 for 5 minutes at 37°C. After incubation, the mixtures were centrifuged for 60 minutes at 105,000 Â g at 4°C, and the supernatants were collected and analyzed by LC-MS/MS. The affinity of the CYP3A4-mediated metabolism (K m value) was determined by fitting one of the following equations (eq. 1 or 2) to the CL int values at the designated unbound substrate concentrations corrected with the unbound fraction in microsomes:
where S represents the initial unbound substrate concentration in the medium corrected with the unbound fraction in microsomes, and V max is the theoretical maximum depletion rate. The fitting was performed with the nonlinear leastsquares method using the MULTI program (http://www.pharm.kyoto-u.ac.jp/ byoyaku/Kinetics/download.html) (Yamaoka et al., 1981) . Verapamil was analyzed by eq. 2 because two saturable components were optically observed. All other substrates were analyzed by eq. 1. The experimental data are shown in Supplemental Fig. 1 . Cell Culture. Caco-2 cells, provided by the Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo (Tokyo, Japan), were cultured at 37°C in a 5% CO 2 atmosphere using Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were passaged upon reaching approximately 80% confluence using trypsin-EDTA and plated at ratios of 1:5. For the preparation of Caco-2 cell monolayers, cells (passage numbers 4-16) were plated in a Corning 24-well Transwell plate (0.33 cm 2 membrane surface area, 6.5 mm diameter; Corning Inc., Tewksbury, MA) at a density of 4.0 Â 10 4 cells/insert. The culture medium was replaced every second day with 250 ml and 1 ml into the apical and basolateral side, respectively. After 21-25 days in culture, the Caco-2 cell monolayers were used for the transport experiments.
In Vitro Assay for P-gp-Mediated Transport. In vitro transcellular transport assays were performed to determine the kinetic parameters for P-gpmediated transport. The Caco-2 cell monolayer was preincubated in Hanks' balanced salt solution (HBSS) with 10 mM HEPES (pH 7.4) for 30 minutes at 37°C. After preincubation, the transepithelial electrical resistance was estimated with the Millicell-ERS system (Millipore Co., Bedford, MA). The Caco-2 monolayers with transepithelial electrical resistance values over 300 Vcm 2 were used in the experiments. Thereafter, an HBSS buffer containing celiprolol (10-1000 mM), digoxin (0.3-30 mM), fexofenadine (1-300 mM), talinolol (3-1000 mM), indinavir (1-30 mM), quinidine (0.3-100 mM), saquinavir (1-30 mM), or verapamil (0.3-100 mM) was added to the apical side (0.25 ml, HBSS, pH 6.5). To determine the passive permeability of substrates, verapamil was coincubated at a concentration of 100 mM. After incubation for 30, 60, and 90 minutes at 37°C, 0.1 ml of the medium was taken from the opposite side. The substrate concentration was determined by LC-MS/MS. The apparent permeability coefficient (P app , cm/s) was calculated using the following equation:
where dQ/dt is the permeation rate (mol/min), A is the surface area of the insert (0.33 cm 2 ), and C 0 is the initial concentration (mM). The kinetic parameter for P-gp-mediated efflux was estimated from the concentrationdependent P app . The K m value with regard to the unbound concentration in the cells was calculated based on the model analysis method (Tachibana et al., 2010) . The overall apical-to-basolateral permeability was shown as eqs. (4) and (5). The affinity of the P-gp-mediated efflux (K m value) was determined by fitting with the following eq. (6):
where PS AB is the permeation clearance in the apical to basolateral direction, PS 1 is the passive permeation clearance from the apical side to cells, PS 2 is the passive permeation clearance from cells to the apical side, and PS 3 is the passive permeation clearance from cells to the basolateral side. PS P-gp is the active efflux clearance mediated by P-gp. Passive permeation clearance was assumed to be the same for each substrate (PS 1 = PS 2 = PS 3 ). Then, a total of three parameters (K m , V max , and PS 1 ) were fitted to the concentration-dependent permeation clearance.
Obvious saturation was not observed on concentration-dependent permeation of celiprolol, digoxin, and saquinavir. Assuming PS P-gp was zero in eq. (4), PS AB can be simply described as follows:
Thus, we could assume that PS AB in the presence of 100 mM verapamil (P-gp inhibitor) was equal to half of the passive permeation clearance. Then, after fixing PS 1 , K m and V max for P-gp were optimized based on the concentrationdependent permeation clearance of substrate drugs. The fitting was performed with the numerical mode by SAAMII version 1.2 (The Epsilon Group, Charlottesville, VA). The experimental data are shown in Supplemental Fig. 2 . Apparent Permeability. The apparent permeability was estimated by an in vitro transcellular transport assay using Caco-2 cells. Assay conditions are described in the In Vitro Assay for P-gp-Mediated Transport section. HBSS buffer containing 1 mM felodipine, 1 mM midazolam, 1 mM sildenafil, 1 mM triazolam, 100 mM atenolol, 100 mM cimetidine, 1 mM ketoprofen, 1 mM metoprolol, 1 mM propranolol, or 100 mM ranitidine was added to the apical side [0.25 ml of HBSS (pH 6.5)]. P-gp substrates, 10 mM celiprolol, 0.3 mM digoxin, 1 mM fexofenadine, 3 mM talinolol, 1 mM indinavir, 1 mM quinidine, or 1 mM saquinavir was added to the apical side with 100 mM verapamil as a P-gp inhibitor. After incubation for 30, 60, and 90 minutes at 37°C, 0.1 ml of the medium was taken from the opposite side and analyzed by LC-MS/MS (experimental data are shown in Supplemental Table 1) .
Protein Binding in Enterocyte. The unbound fraction in enterocytes was estimated by equilibrium dialysis using a Rapid Equilibrium Dialysis (RED) device (Thermo Fisher Scientific Inc., Waltham, MA) or a 96-well Equilibrium DIALYZER plate with a molecular weight cutoff of 10,000 Da (Harvard Apparatus, Holliston, MA). Twenty-nine percent human intestine homogenate was diluted to obtain 7, 14, and 21% homogenate containing 3 mM felodipine, 50 mM midazolam, 10 mM sildenafil, 50 mM triazolam, 100 mM celiprolol, 100 mM digoxin, 100 mM fexofenadine, 100 mM talinolol, 10 mM indinavir, 100 mM quinidine, 10 mM saquinavir, and 100 mM verapamil with phosphate-buffered saline at pH 7.4. Aliquots (75 ml; 96-well Equilibrium DIALYZER, 100 ml; RED device) of each sample and phosphate-buffered saline (75 ml; 96-well Equilibrium DIALYZER, 300 ml; RED device) were added to the equilibrium dialysis device. The plate was put into a 37°C incubator and gently stirred for 4 hours. After incubation, 30 ml of samples and buffers was removed and mixed with 50 ml of acetonitrile containing an internal standard. The mixture was centrifuged for 5 minutes at 20,400 Â g at 4°C, and the supernatants were collected. Substrate concentration was determined by LC-MS/MS.
Solubility. pH-dependent solubility of felodipine, midazolam, sildenafil citrate, digoxin, fexofenadine hydrochloride, indinavir, quinidine sulfate, saquinavir, and verapamil hydrochloride was determined. Acetate buffer (0.1 M, pH 4 and 5), 0.1 M phosphate buffer (pH 6, 7, and 8), and glycineNaOH buffer (pH 9 and 10) were prepared. Excess amounts of substrate were added to each different pH buffer and incubated for 24 hours at 25°C. After incubation, the suspensions were centrifuged for 5 minutes at 20,400 Â g at 25°C, and the supernatants were filtered through a Millipore Millex-HA filter 0.45 mm. The substrate concentration was determined by LC-MS/MS. The pH was determined using a pH meter (Shindengen, Tokyo, Japan). The pK a and solubility factor (defined as a ratio of the solubility of completely ionized drug to completely unionized drug) of each compound were derived by fitting the preinstalled model, named "Solubility vs. pH Model version 6.1" in GastroPlus (Simulations Plus, Inc., Lancaster, CA) to all of the solubility data at the different pH values tested (experimental data are shown a F h was calculated using a hepatic blood flow rate of 25.5 ml/min/kg (Wynne et al., 1989) , except for felodipine. b F h for felodipine was calculated using a hepatic blood flow rate of 43.4 ml/min/kg (Bengtsson-Hasselgren et al., 1990 Table 2 ). The pK a and solubility factor of triazolam, celiprolol, and talinolol were calculated by the reported solubility data (package insert of triazolam; Kobayashi Kako Co., Ltd., Fukui, Japan) (Gramatté et al., 1996; Bergström et al., 2004) . LC-MS/MS Analysis. Three LC-MS/MS systems-a Quattro micro API tandem mass spectrometer equipped with an alliance 2695 separation module (Waters, Milford, MA), an AB SCIEX QTRAP 5500 mass spectrometer (AB SCIEX, Foster City, CA) equipped with a prominence liquid chromatograph (Shimadzu, Kyoto, Japan), and an AB SCIEX API-4000 mass spectrometer (AB SCIEX) equipped with a Agilent 1100 series liquid chromatograph (Agilent Technologies, Santa Clara, CA)-were used for the determination of compounds. The mass spectrometers were operated in positive-ion electrospray ionization and multiple-reaction monitoring mode for the detection of compounds. The details of the LC conditions and multiple-reaction monitoring transitions are shown in Supplemental Table 2 .
The collected supernatants were diluted with the mobile phase. The diluted samples (10 ml) were injected into the LC-MS/MS connected with an Atlantis T3 column (2.1 Â 50 mm, 5 mm; Waters). The range of calibration curve of each compound was 0.01-10 mmol/l (felodipine), 0.1-10 mmol/l (sildenafil), 1-1000 nmol/l (celiprolol), 0.1-100 nmol/l (digoxin), 0.3-300 nmol/l (fexofenadine), 1-300 nmol/l (talinolol), 0.003-10 mmol/l (indinavir), 1-3000 nmol/l (quinidine, verapamil), and 1-100 nmol/l (midazolam, triazolam, atenolol, cimetidine, ranitidine, metoprolol, propranolol, ketoprofen) . The correlation coefficient of calibration curve was over 0.990 in all analysis.
Intestinal Availability. The total clearance (CL tot ), renal clearance (CL r ), and blood-to-plasma concentration ratio (R b ) were calculated from literature information. Bioavailability (F), hepatic availability (F h ), and F a F g values are shown in Table 1 . F a F g was calculated using the following equation:
where AUC po , AUC iv , Dose po , Dose iv , CL h , F h , and Q h are plasma area under the concentration-time curve (AUC) after oral administration, plasma AUC after intravenous administration, dose on oral administration, dose on intravenous administration, hepatic blood clearance, hepatic availability, and hepatic blood flow rate, respectively. The Q h was set at 25.5 ml/min/kg (Wynne et al., 1989 ) except for felodipine. According to a previous report, felodipine caused a 1.7-fold increase in the Q h after oral dosing (Bengtsson-Hasselgren et al., 1990) . Thus, the Q h was set at 43.4 ml/min/kg for felodipine only. Pharmacokinetic parameters were obtained from previous reports shown in Table 1 . F a F g estimated from the clinical pharmacokinetic study was defined as "observed F a F g ," whereas F a F g calculated by the simulation of the ACAT model with in vitro and in silico parameters was defined as "predicted F a F g ." In cases where the body weight of subjects was unknown in a clinical study report, it was Fig. 1 . The outline of our strategy of the prediction of intestinal availability. F a F g was predicted from physiochemical and in vitro kinetic parameters of drugs with the ACAT model. SF CYP3A and SF P-gp were simultaneously estimated from the relationship between predicted and observed F a F g . Table 6 were conducted under nonfasted conditions (Nakashima et al., 1988; Greenblatt et al., 1998a,b; Hsu et al., 1998) . Conditions of food intake in clinical studies of celiprolol and fexofenadine could not be obtained from previous reports (Caruso et al., 1985; Lappin et al., 2010) . All other clinical studies after oral administration, shown in Table 1 and Table 6 , were conducted under fasted conditions. ACAT Model. GastroPlus version 9.0 was used for quantitative prediction of nonlinear intestinal absorption. The human physiologic fasted model and Opt logD model were used in the ACAT model. As shown in Supplemental Table 3 , default values in version 6.1 were used for physiologic parameters (intestinal length, radius, pH, transit time, and regional distribution factors for CYP3A4 and P-gp) in GastroPlus. Oral administrations in all clinical studies shown in Table 1 and Table 6 were conducted using oral solution, capsule, or tablet, not including controlledrelease formulations. Thus, we assumed immediate-release formulation at oral administration in the ACAT model. The time length of calculation for all substrates was set to 48 hours after dosing. CYP3A4-mediated gut metabolism and P-gp-mediated efflux were defined in the ACAT model. GastroPlus includes the physiologic expression level of CYP3A4 in each segment of the human intestine to adjust the V max for gut enzymes. In contrast, since the absolute expression level of P-gp was lacking, V max was calculated based on the relative expression level in each segment. The SFs are included in the equation for gut metabolism and the efflux and influx transport in GastroPlus. These are empirical SFs which can be optimized to fit the predicted F a F g to explain the observed F a F g . In the ACAT model, the F a F g value was defined as the fraction of administered drugs that reach the portal blood. Each process of intestinal absorption was calculated using following equations:
where k a , P eff , R, L, i, j, dM absorbed /dt, V, C lumen , C ent , SF Vmax , SF Km , ESF i,j , and f ue are absorption rate constant, effective permeability, radius of the compartment, length of the compartment, the index for the i th enzyme or influx/efflux transporter, the index for the j th intestine compartment, absorption rate, volume of intestinal lumen, drug concentration in the lumen, drug concentration in the enterocytes, SF for V max (default = 1), SF for K m (default = 1), regional distribution factors for enzyme or transporter i in compartment j, and the unbound fraction in enterocytes, respectively. The maximum Cu ent (unbound concentration in the enterocyte compartment) was calculated as the maximum concentration among all intestinal compartments in the ACAT model. P eff in humans is calculated by measuring the rate of disappearance of a drug from a section of the gastrointestinal tract at steady state. In this study, P eff was converted from P app of Caco-2 cells by the following regression equation (Sun et al., 2002) :
where P eff and P app are expressed in (Â10 24 cm/s) and (Â10 26 cm/s). A and B are coefficients, which were calculated to be 20.162 and 0.6447 based on P eff and P app of reference compounds. P eff of a test substrate was converted from its P app with optimized coefficients A and B with eq. 18. Consideration of CYP3A5-Mediated Metabolism. The expression level of CYP3A5 in each segment of human intestine is not defined in the GastroPlus default settings. The mean expression level of CYP3A5 was calculated from the literature. Lin et al. (2002) reported that the CYP3A4 and CYP3A5 expression levels in jejunal homogenate were 17.2 and 14.0 pmol/mg protein in CYP3A5*1/ *1 subjects, 2.4 and 3.6 pmol/mg protein in CYP3A5*1/*3 subjects, and 18.2 and 0.5 pmol/mg protein in CYP3A5*3/*3 subjects, respectively. The allelic frequency of CYP3A5 was calculated as the weighted average from Caucasian kidney transplant patients (Haufroid et al., 2004; Mai et al., 2004) . The frequency of CYP3A5*1/*1, CYP3A5*1/*3, and CYP3A5*3/*3 were calculated to be 1, 14, and 85%, respectively. The mean expression levels of CYP3A4 and CYP3A5 were calculated using the following equation:
where i is the index of the i th genotype. The calculated mean expression levels of CYP3A4 and CYP3A5 were 16.0 and 1.07 pmol/mg protein, respectively. Assuming that the ratio of CYP3A4/CYP3A5 expression is constant in each segment of the human intestine, the CYP3A5 expression level was defined in GastroPlus. SF CYP3A was defined as a common parameter for both CYP3A4 and CYP3A5.
Optimization of SF CYP3A and SF P-gp . Our analysis strategy is shown in Fig. 1 . In the ACAT model in the GastroPlus software, predicted gut metabolism rate and efflux rate were estimated based on eqs. 15 and 17. We assumed that in vivo K m values of drugs are the same as those obtained from in vitro experiments for P-gp and CYP3A. The ESF value for CYP3A is set up based on the absolute expression level of CYP3A in the gut preset in GastroPlus. Since the absolute expression level of P-gp in each region of the intestine has not been clarified, the relative expression level of each compartment is set as the ESF value for P-gp. One of the critical points required to construct an accurate model is to determine appropriate SF CYP3A and SF P-gp . SF CYP3A and SF P-gp should be common parameters for all substrates of CYP3A and P-gp, respectively. We selected 12 test compounds, including four P-gp substrates which are not metabolized by CYP3A (celiprolol, digoxin, fexofenadine, and talinolol), four CYP3A substrates which are not transported by P-gp (felodipine, midazolam, sildenafil, and triazolam), and four dual substrates of CYP3A and P-gp (indinavir, quinidine, saquinavir, and verapamil), based on the literature (Tachibana et al., 2012) to collect abundant information on the relationship between kinetic parameters for P-gp and CYP3A and intestinal availability of various drugs to clearly discriminate the contribution of P-gp and CYP3A. Clinical data for quinidine at doses of 0.1 and 1 mg and verapamil at doses of 0.1 and 3 mg were used for our analyses. SF CYP3A and SF P-gp were optimized by simultaneous fitting of predicted F a F g values (using GastroPlus based on in vitro parameters of all test compounds) to clinically observed ones.
The optimization module was used to optimize the SF for V max . The objective function was constructed from the predicted and observed F a F g :
where W is weight. SF CYP3A and SF P-gp were simultaneously optimized to explain the F a F g of selective and dual CYP3A and/or P-gp substrate drugs. The weight was set at 1/F a F g Observed . If the observed F a F g of substrates under linear conditions was available, this was applied to the optimization of SFs. The bias and precision of prediction of F a F g were evaluated using average fold error (afe) and root mean squared error (rmse) (Sheiner and Beal, 1981; Obach et al., 1997) , as follows:
Results
In Vitro Experimental Data for Predicting the Intestinal Absorption of Drugs. Physicochemical parameters for each drug to predict the intestinal absorption of CYP3A and P-gp substrates are shown in Table 2 . The passive permeability and the unbound fraction in enterocytes are shown in Table 3 . The estimated P eff for each substrate was calculated from the P app estimated in Caco-2 cells. The kinetic parameters for CYP3A4 and P-gp are shown in Tables 4 and 5. All CYP3A substrates showed saturation kinetics, and their metabolic clearances showed 50-fold difference from 0.00423 ml/min/pmol P450 Fig. 2 . Comparison of the predicted (pred.) and observed (obs.) intestinal availabilities of CYP3A and P-gp substrates. (A) Before optimization, F a F g was predicted by only considering the membrane permeation by passive diffusion. CYP3A-mediated metabolism and P-gp-mediated efflux were not considered. (B) After optimization, F a F g was predicted with optimized SF CYP3A and SF P-gp . The broken line represents a 1.5-fold deviation from the unity. CYP3A substrates are felodipine (1), midazolam (2), sildenafil (3), and triazolam (4). P-gp substrates are celiprolol (5), digoxin (6), fexofenadine (7), and talinolol (8). Dual substrates are indinavir (9), quinidine 0.1 mg (10-1), quinidine 1 mg (10-2), saquinavir (11), verapamil 0.1 mg (12-1), and verapamil 3 mg (12-2).
Predictive Model for Nonlinear Intestinal Absorption 1813
at ASPET Journals on November 6, 2017 dmd.aspetjournals.org of quinidine to 0.211 ml/min/pmol P450 of felodipine. Tachibana et al. (2010) calculated the kinetic parameters for P-gp-mediated efflux with regard to the intracellular unbound concentration in Caco-2 cells. This method was used to estimate the K m and V max values for P-gp.
The efflux clearance of 12 tested drugs showed 50-fold difference from 1.18 ml/min/10 6 cells of verapamil to 63.6 ml/min/10 6 cells of saquinavir. The selective and dual CYP3A and/or P-gp substrates selected in this study showed a wide range of metabolic and efflux clearances. The metabolic clearances of CYP3A4 and CYP3A5 are shown in Supplemental Table 4 . Midazolam showed the highest metabolic clearance ratio of CYP3A5/CYP3A4 (1.86), whereas quinidine had the lowest value (0.299) among the CYP3A substrates. The calculated mean expression level of CYP3A4 in the intestine was 10.8-fold higher than that of CYP3A5, thus contribution of CYP3A5 to the intestinal metabolism was expected to be minor compared with CYP3A4.
Optimization of SF CYP3A and SF P-gp to Determine the Ratio of Their Expression Levels between In Vitro Experimental Systems and In Vivo Intestine. As shown in Fig. 2A , most of the substrates were well absorbed when both CYP3A-mediated metabolism and P-gpmediated efflux were not considered. Then, SF CYP3A and SF P-gp were defined as the ratio of their functions between in vitro experimental systems and in vivo intestine and optimization was attempted to minimize the differences between observed and predicted F a F g values of 12 drugs. The optimized SF CYP3A and SF P-gp values were calculated to be 0.0740 and 0.00651, respectively. After optimization of SF CYP3A and SF P-gp , the predicted F a F g values of 8 of 12 substrates were within 1.5-fold deviations from the observed ones. As shown in Table 6 , to estimate the relative contribution of CYP3A and P-gp in the intestinal absorption, the simulation was performed under four different conditions: both the optimized SF CYP3A and SF P-gp were used (SF CYP3A = 0.0740, SF P-gp = 0.00651, simulation I), only the optimized SF CYP3A was used and P-gp-mediated efflux was not considered (SF CYP3A = 0.0740, SF P-gp = 0, simulation II), only the optimized SF P-gp was used and CYP3A-mediated metabolism was not considered (SF CYP3A = 0, SF P-gp = 0.00651, simulation III), and both P-gp-mediated efflux and CYP3A-mediated metabolism were not considered (SF CYP3A and SF P-gp = 0, simulation IV). In simulations II and III, the F a F g values were overestimated for the P-gp and CYP3A substrates, respectively. The overall predictability of F a F g values of 12 CYP3A and/or P-gp substrates was best improved when considering both SF CYP3A and SF P-gp since simulation I showed the lowest afe and rmse values.
Prediction of Dose-Dependent F a F g of CYP3A/P-gp Substrate Drugs with Predefined SFs. To further verify the predictability of dose-dependent F a F g of several CYP3A/P-gp substrate drugs with our approach, we predicted the dose-dependent F a F g of substrates by using the ACAT model with our optimized SFs. The predicted F a F g values and their ratio to that at minimum dose, and the observed AUC/dose ratio to that at minimum dose obtained from the clinical reports are shown in Table 7 . The predicted F a F g ratios of triazolam, celiprolol, digoxin, fexofenadine, and indinavir were constant in their clinical dose range. In contrast, the predicted F a F g ratios of felodipine, midazolam, sildenafil, talinolol, quinidine, and verapamil increased in a dose-dependent manner, whereas that of saquinavir decreased.
Discussion
In this study, we tried to establish an appropriate method for the quantitative prediction of the dose-dependent F a F g of drugs based on the in vitro saturation kinetics of CYP3A and P-gp using a mathematical model for the small intestine. SF CYP3A and SF P-gp were simultaneously optimized to well explain the F a F g of selective and dual CYP3A and/or P-gp substrate drugs. The best overall predictability of F a F g values of these drugs was achieved when considering both SF CYP3A and SF P-gp .
To consider the relative importance of CYP3A4 and CYP3A5 in the intestine, when considering only CYP3A4-mediated metabolism in the intestine, the optimized SF CYP3A and SF P-gp were estimated to be 0.0811 and 0.00643, which are comparable to the default SFs (0.0740 and 0.00651). This result indicated that CYP3A5-mediated metabolism had a minor contribution to the intestinal absorption of tested substrates.
When the F a F g of substrates was calculated considering only the passive permeability, the predicted F a F g of most substrates was close to 100%, and was not consistent with the observed F a F g (Fig. 2A) . This result indicated that all of the tested substrates had good transcellular permeability, and that P-gp and CYP3A were clearly involved in suppressing the intestinal absorption of those substrates. After optimization of SF CYP3A and SF P-gp , the predicted F a F g values of 8 of 12 substrates were within 1.5-fold deviations from the observed F a F g . 1814 Takano et al.
Therefore, our method can quantitatively predict the F a F g of CYP3A/ P-gp substrates. However, the predicted F a F g value of indinavir with optimized SF CYP3A and SF P-gp was 0.113, which was much lower than the observed F a F g (Fig. 2B) . When comparing the observed F a F g of drugs with the predicted ones in simulation IV (assuming that both intestinal P-gp and CYP3A are not functional), only predicted F a F g of indinavir was lower than the observed one (Table 6 ). One of the explanations for this discrepancy is that solubility of indinavir in the intestinal lumen was underestimated in our model. Actually, the simulated dissolved fraction in the intestinal lumen estimated with our ACAT model (Supplemental Table 5 ) revealed that all of the tested substrates, except for indinavir and saquinavir, were well dissolved at 48 hours after dosing. Gertz et al. (2011) performed F g prediction of CYP3A substrates with a physiologically-based pharmacokinetic model using in vitro clearance data and solubility in fasted state-simulated intestinal fluid (FaSSIF). It has been reported that the solubilities of indinavir in FaSSIF (pH 6.5) and fed state-simulated intestinal fluid (FeSSIF; pH 5.0) are 0.048 and 1.4 mg/ml, respectively (Holmstock et al., 2013) , whereas those of indinavir in the buffer at pH 6.1 and 5.1 in our experiment were 0.035 and 0.18 mg/ml, respectively. The solubility in FaSSIF was comparable to that in buffer, whereas the solubility in FeSSIF was 8-fold higher than that in buffer. The clinical study of indinavir was conducted under fasted condition (Yeh et al., 1999) . The underestimation of predicted F a F g of indinavir is not improved, even if the solubility in FaSSIF is used for the simulation. Assuming that solubility in buffer was 8-fold higher at each pH, the predicted F a F g of indinavir with optimized SF CYP3A and SF P-gp increased to 0.530. The solubility of saquinavir in FeSSIF at pH 6.5 was reported as 0.456 mg/ml (Kawai et al., 2011) , which is 2-fold higher than that in the buffer (0.239 mg/ml at pH 6.9). The predicted F a F g of saquinavir was increased to 0.0631 considering the similar assumption of high solubility as indinavir. Thus, by considering the solubility in simulated intestinal 
, where f ub , C max,b , k a , F a F g , and Q h are the unbound fraction in blood, maximum drug concentration in blood in clinical study, absorption rate constant, intestinal availability, and hepatic blood flow rate. k a , F a F g , and Q h were assumed to be 0.1 min 21 , 1, and 99.5 l/h. fluid, the predicted F a F g of indinavir largely approached the real one, whereas that of saquinavir was still maintained as low. GastroPlus incorporates the effect of bile salts on the solubility of drug in the gastrointestinal tract by taking into account the solubilization by bile salts. For indinavir, predicted F a F g was estimated to be 0.331 under fed conditions considering the effect of bile acids. Thus, for low-solubility compounds, the predictability of F a F g may be improved by considering the effect of bile acid, and the estimation of solubility needs to be further optimized. When we tried to perform an optimization of SFs for P-gp and CYP3A without using the data for indinavir, SF CYP3A and SF P-gp were estimated to be 0.0781 and 0.00682, respectively, which were almost the same as the optimized SFs with all substrates (SF CYP3A = 0.0778 and SF P-gp = 0.00651). Thus, the inclusion of indinavir in the test set did not largely affect the optimized SFs in this study. Using the ACAT model with our optimized SFs, the relative importance of CYP3A and P-gp to the intestinal absorption of drugs was also estimated. As for verapamil, its predicted F a F g was identical between simulations I and II, but the predicted F a F g was higher than the observed one in simulation III. This result suggested that CYP3A is the main contributor to the low F a F g of verapamil. Conversely, the predicted F a F g of quinidine was higher than the observed one in both simulations II and III, suggesting both CYP3A and P-gp contributed to the low F a F g of quinidine. We previously demonstrated that the dose-normalized plasma AUCs of verapamil and quinidine increased in a dose-dependent manner, possibly due to the saturation of P-gp and CYP3A in the gut . As shown in Fig. 3 , the dose-dependent F a F g values of verapamil and quinidine were well reproduced with the optimized SF CYP3A and SF P-gp . Moreover, nonlinear intestinal absorption of verapamil was dominated by the saturation of intestinal CYP3A, whereas that of quinidine was caused by the saturation of both CYP3A and P-gp. In the case of saquinavir, which is a dual substrate of CYP3A and P-gp, its predicted F a F g values in simulations I and III were identical. However, in simulation II, the predicted F a F g of saquinavir was higher than the observed one. This result suggested that P-gp mainly contributed to the low F a F g of saquinavir at clinical dose. Due to the low K m value (0.395 mM) of saquinavir for CYP3A4, intestinal CYP3A4 was thought to be completely saturated at clinical dose.
We also predicted the dose-dependent F a F g of substrates with the optimized SFs (Table 7) . Felodipine, midazolam, sildenafil, talinolol, quinidine, and verapamil showed nonlinear pharmacokinetics in previous clinical studies (Bornemann et al., 1985; Nakashima et al., 1992; Wetterich et al., 1996; Nichols et al., 2002; . Their predicted F a F g ratios increased in a similar manner as the dosedependent increase in the observed AUC/dose ratios. Cu in max at a high dose of quinidine (200 and 600 mg) was higher than the K m value for CYP3A, indicating hepatic CYP3A would be saturated. In contrast, the predicted F a F g of indinavir did not change as the dose increased. Intestinal CYP3A was saturated at 400 mg because predicted F a F g was not changed between simulations I and III in Table 6 . Since the Cu in max of indinavir (17.5 mM at 400-mg dose) was much higher than its K mCYP3A4 , its supraproportional AUC increase with dose was possibly due to the saturation of hepatic CYP3A, as previously reported (Ke et al., 2012) . Although celiprolol showed nonlinear pharmacokinetics in the clinical dose range, the predicted F a F g of celiprolol was constant at different doses. Celiprolol is a substrate of efflux transporter (P-gp) and influx transporter (OATP2B1) on the apical membrane of enterocytes. In our in vitro assay with Caco-2 cells, the concentration-dependent nonlinear transcellular transport was not observed. It has been reported that OATP2B1 is expressed on Caco-2 cells (Englund et al., 2006) . Both influx and efflux transporters may have been involved in transcellular transport of celiprolol. However, we could not find any clear reasons for such discrepancy. According to the clinical report, the AUC/dose ratio of saquinavir decreased at higher doses. The predicted F a F g ratio of saquinavir also decreased dose dependently, and was close to the clinically observed AUC/dose ratios. Cu in max and maximum Cu ent of saquinavir at doses of 400 and 600 mg were higher than K CYP3A4 (Table 7) , suggesting hepatic and intestinal CYP3A-mediated metabolism was expected to be saturated. In addition, due to the low solubility of saquinavir (simulated solubility; 0.44 mg/ml at pH 6.5), drug absorption would be limited by solubility. Therefore, nonlinear pharmacokinetics of saquinavir may be caused by complex mechanisms, such as saturation of both metabolism and dissolution. Previous reports demonstrated that triazolam, digoxin, and fexofenadine showed linear pharmacokinetics within the clinical dose range (Table 7) . Their predicted F a F g values were maintained as constant at different doses. Overall, the dose-dependent F a F g was well predicted even if substrates showed nonlinear intestinal absorption.
In conclusion, using the optimized SF CYP3A and SF P-gp based on the data of 12 P-gp and/or CYP3A substrate drugs, F a F g can be well predicted by in vitro parameters for CYP3A and P-gp using the ACAT model. The linearity of the dose-dependent intestinal absorption of those Fig. 3 . Role of CYP3A and P-gp in the nonlinear intestinal absorption of verapamil and quinidine. Intestinal availability after oral administration of verapamil at a dose range of 0.1-80 mg (A) and that of quinidine at a dose range of 0.1-100 mg (B) were simulated. Simulation was performed using optimized SF CYP3A and SF P-gp (2 2 2), optimized SF CYP3A and SF P-gp = 0 (2 • 2), SF CYP3A = 0 and optimized SF P-gp (• • •), and SF CYP3A and SF P-gp = 0 (--). Square symbols represent the mean F a F g value observed in vivo. Each point represents the mean 6 S.D. [n = 8 (verapamil) and 7 (quinidine)].
1816 Takano et al. at ASPET Journals on November 6, 2017 dmd.aspetjournals.org drugs could be theoretically judged by incorporating kinetic parameters estimated by in vitro experiments into the ACAT model. We determined that one of the key points to successfully obtain universal SFs is to use the reliable kinetic parameters obtained from unified in vitro experiments, since their large interlaboratory differences were reported. Once in-house SFs are set up with a set of test compounds, F a F g of a new compound can surely be predicted at any dose from in vitro data.
